Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers

Trial Profile

A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Dec 2018

At a glance

  • Drugs Galinpepimut S (Primary) ; Pembrolizumab (Primary)
  • Indications Acute myeloid leukaemia; Adenocarcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Sellas Life Sciences Group
  • Most Recent Events

    • 20 Dec 2018 Planned End Date changed from 15 Jan 2021 to 28 Feb 2021.
    • 20 Dec 2018 Planned primary completion date changed from 15 Jul 2020 to 31 Aug 2020.
    • 20 Dec 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top